Market Place
Sourcing Support
All News #Library
Biotech
Neurogene To Present Therapeutic Rationale For ICV Delivery
28 Apr 2026 //
PHARMIWEB
Neurogene Discloses Inducement Grants Under Nasdaq Rule
08 Apr 2026 //
PHARMIWEB
Neurogene Unveils 2025 Financials, Highlights Recent Progress
24 Mar 2026 //
PHARMIWEB
Neurogene To Participate In Stifel 2026 Virtual CNS Forum
11 Mar 2026 //
PHARMIWEB
Neurogene Reveals Inducement Grants Per Nasdaq LR 5635(C)(4)
03 Mar 2026 //
BUSINESSWIRE
Neurogene To Participate In Upcoming Investor Conferences
05 Feb 2026 //
BUSINESSWIRE
Neurogene Reveals Inducement Grant Per Nasdaq LR 5635(C)(4)
04 Feb 2026 //
BUSINESSWIRE
Neurogene To Join 44Th J.P. Morgan Healthcare Conference
05 Jan 2026 //
BUSINESSWIRE
Neurogene Reveals Inducement Grants Per Nasdaq LR 5635(C)(4)
04 Dec 2025 //
BUSINESSWIRE
Neurogene Unveils Q3 2025 Financials And Recent Developments
13 Nov 2025 //
BUSINESSWIRE
Neurogene Grants Inducement Under Nasdaq LR 5635(C)(4)
05 Nov 2025 //
BUSINESSWIRE
Neurogene Participate in HC Wainwright Genetic Medicines Conf
08 Oct 2025 //
BUSINESSWIRE
Neurogene Inducement Grants Under Nasdaq Lr 5635(C)(4)
03 Oct 2025 //
BUSINESSWIRE
Neurogene Reveals Trial Design for NGN-401 Gene Therapy
30 Jun 2025 //
BUSINESSWIRE
Neurogene to Present on Rare Complication Reversal at ASGCT Meeting
28 Apr 2025 //
BUSINESSWIRE
Patient put in critical condition by Neurogene gene therapy dies
23 Nov 2024 //
BIOSPACE
Neurogene Details Gene Therapy Issue, Shares Plummet Again
18 Nov 2024 //
BIOSPACE
Neurogene Reports Positive NGN-401 Data in Pediatric Rett Syndrome
11 Nov 2024 //
BUSINESSWIRE
Neurogene Presents Interim Data From NGN-401 Trial For Rett Syndrome
21 Oct 2024 //
BUSINESSWIRE
Neurogene Reports Q2 2024 Results And Recent Updates
09 Aug 2024 //
BUSINESSWIRE
Neurogene`s NGN-401 For Rett Syndrome Receives RMAT Designation
07 Aug 2024 //
BUSINESSWIRE
Neurogene`s NGN-401 Rett Syndrome Gene Therapy In FDA START Program
03 Jun 2024 //
BUSINESSWIRE
Neurogene Rett Data At ASGCT Annual Meeting
07 May 2024 //
BUSINESSWIRE
Neurogene Presenting NGN-401 Rett Syndrome Gene Therapy Safety Data
22 Apr 2024 //
BUSINESSWIRE
Neurogene Announces Expansion for Enrollment of Rett Syndrome Gene Therapy Trial
04 Mar 2024 //
BUSINESSWIRE
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401
30 Nov 2023 //
BUSINESSWIRE
Neurogene inks Neoleukin reverse merger to fund gene therapies
18 Jul 2023 //
FIERCE BIOTECH
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.